Drug Trial Radar · NCT00710619
Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
Last checked: Nov 19, 2026Latest source record: Nov 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jun 2008
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 4, 2008
Design
- Study type
- Observational
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted in the United States of America (USA). The aim of this study is to investigate the at-home-administration of bypassing agents for treatment of bleeding episodes in patients with congenital haemophilia with inhibitors to factors VIII and IX. We are further investigating how bleeding episodes affect the quality of life of the patient and their family or caregivers.
Conditions
- Congenital Bleeding Disorder
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VIIDrug
This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
Feiba VHDrug
This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterisation of dose and dosing intervals for each bleeding episodeTime frame: after 3-6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Plainsboro, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.